Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (**Currently Amended**). A compound which is **crystalline** carvedilol dihydrogen phosphate hemihydrate.

2 (Original). The compound according to claim 1 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta as shown in Figure 1.

3 (Original). The compound according to claim 2 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 7.0 ± 0.2 (2θ), 11.4 ± 0.2 (2θ), 15.9 ± 0.2 (2θ), 18.8 ± 0.2 (2θ), 20.6 ± 0.2 (2θ), 22.8 ± 0.2 (2θ), and 25.4 ± 0.2 (2θ).

4 (**Previously Presented**). The compound according to claim 1 having an infrared spectrum which comprises characteristic absorption bands expressed in wave numbers as shown in Figure 6.

5 (Original). The compound according to claim 1 having a Raman spectrum which comprises characteristic peaks as shown in Figure 3.

6 (Original **/Withdrawn**). A compound which is carvedilol dihydrogen phosphate dihydrate.

7 (Original **/Withdrawn**). The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 9.

8 (Original **/Withdrawn**). The compound according to claim 7 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.5 ± 0.2 (2θ), 7.1 ± 0.2 (2θ), 13.5 ± 0.2 (2θ), 14.0 ± 0.2 (2θ), 17.8 ± 0.2 (2θ), 18.9 ± 0.2 (2θ), and 21.0 ± 0.2 (2θ).

9 (Original **/Withdrawn**). The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 25.

10 (Original **/Withdrawn**). The compound according to claim 9 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.4 ± 0.2 (2θ), 9.6 ± 0.2 (2θ), 16.0 ± 0.2 (2θ), 18.4 ± 0.2 (2θ), 20.7 ± 0.2 (2θ), and 24.5 ± 0.2 (2θ).

11 (Original **/Withdrawn**). A compound which is carvedilol dihydrogen phosphate methanol solvate.

12 (Original **/Withdrawn**). The compound according to claim 11 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 24.

13 (Original **/Withdrawn**). The compound according to claim 12 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.9 ± 0.2 (2θ), 7.2 ± 0.2 (2θ), 13.5 ± 0.2 (2θ), 14.1 ± 0.2 (2θ), 17.8 ± 0.2 (2θ), and 34.0 ± 0.2 (2θ).

14 (Original **/Withdrawn**). A compound which is carvedilol dihydrogen phosphate.

15 (Original **/Withdrawn**). The compound according to claim 14 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 28.

16 (Original **/Withdrawn**). The compound according to claim 15 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 13.2 ± 0.2 (2θ), 15.8 ± 0.2 (2θ), 16.3 ± 0.2 (2θ), 21.2 ± 0.2 (2θ), 23.7 ± 0.2 (2θ), and 26.0 ± 0.2 (2θ).

17 (Original **/Withdrawn**). A compound which is carvedilol hydrogen phosphate.

18 (Original **/Withdrawn**). The compound according to claim 17 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 29.

19 (Original **/Withdrawn**). The compound according to claim 18 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 5.5 ± 0.2 (2θ), 12.3 ± 0.2 (2θ), 15.3 ± 0.2 (2θ), 19.5 ± 0.2 (2θ), 21.6 ± 0.2 (2θ), and 24.9 ± 0.2 (2θ).

20 (Original). A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

21 (Original **/Withdrawn**). A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable carrier.

22 (Original **/Withdrawn**). A pharmaceutical composition comprising the compound according to claim 14 and a pharmaceutically acceptable carrier.

23 (Original **/Withdrawn**). A pharmaceutical composition comprising the compound according to claim 17 and a pharmaceutically acceptable carrier.

24 (Original **/Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 1.

25 (Original **/Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 6.

26 (Original **/Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 14.

27(Original **/Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 17.

28 (Original **/Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 20.

29 (Original /**Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 21.

30 (Original /**Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 22.

31 (Original /**Withdrawn**). A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 23.